CBIO Crescent Biopharma Inc.

Price (delayed)

$18.475

Market cap

$509.39M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$11.82

Enterprise value

$321.66M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 19

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is ...

Highlights
CBIO's quick ratio has soared by 108% QoQ
The company's EPS has surged by 84% YoY and by 8% QoQ
Crescent Biopharma's equity has decreased by 9% from the previous quarter
Crescent Biopharma's net income has decreased by 5% QoQ

Key stats

What are the main financial stats of CBIO

CBIO stock price

How has the Crescent Biopharma stock price performed over time
Intraday
2.75%
1 week
-13.95%
1 month
3.1%
1 year
-12.02%
YTD
55.78%
QTD
0.57%

Financial performance

How have Crescent Biopharma's revenue and profit performed over time
Revenue
$10.84M
Gross profit
$10.84M
Operating income
-$164.18M
Net income
-$162.08M
Gross margin
100%
Net margin
-1,494.6%
The operating margin has declined by 8% since the previous quarter
Crescent Biopharma's operating income has decreased by 8% from the previous quarter
Crescent Biopharma's net income has decreased by 5% QoQ
The net margin has declined by 5% since the previous quarter

Price vs fundamentals

How does CBIO's price correlate with its fundamentals

Growth

What is Crescent Biopharma's growth rate over time

Valuation

What is Crescent Biopharma stock price valuation
P/E
N/A
P/B
2.77
P/S
51.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
29.66
The company's EPS has surged by 84% YoY and by 8% QoQ
CBIO's price to book (P/B) is 108% higher than its last 4 quarters average of 1.3 and 42% higher than its 5-year quarterly average of 1.9
Crescent Biopharma's equity has decreased by 9% from the previous quarter

Efficiency

How efficient is Crescent Biopharma business performance
The ROE has soared by 91% YoY and by 24% from the previous quarter
Crescent Biopharma's return on assets has surged by 66% YoY and by 22% QoQ
The company's return on sales fell by 6% QoQ

Dividends

What is CBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CBIO.

Financial health

How did Crescent Biopharma financials performed over time
Crescent Biopharma's current ratio has surged by 110% QoQ
CBIO's quick ratio has soared by 108% QoQ
The debt is 99% smaller than the equity
Crescent Biopharma's equity has decreased by 9% from the previous quarter
The debt has declined by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.